The emerging role of PPARs in primary biliary cholangitis - PubMed
4 hours ago
- #bile acids
- #liver disease
- #PPAR
- Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease affecting bile ducts, leading to fibrosis and cirrhosis.
- Ursodeoxycholic acid is the first-line treatment, but up to 40% of patients have an inadequate response with persistent symptoms.
- New drugs elafibranor and seladelpar, which activate PPARs, have been approved to address this therapeutic gap.
- PPAR-targeting drugs work by regulating immune responses, reducing bile acid toxicity, and inhibiting hepatic fibrosis.
- The review discusses mechanisms, current knowledge, and ongoing challenges in using PPAR agonists for PBC treatment.